Colchicine in Coronary Artery Bypass Graft (CABG)

G.Gennimatas General Hospital

Status and phase

Completed

Phase 4

Conditions

Elective Coronary Artery Bypass Graft Surgery

Treatments

Drug: Colchicine

Study type

Interventional

Funder types

Other

Identifiers

NCT02122484

COL.CABG

Details and patient eligibility

About

There is evidence that inflammatory processes may play a key role during surgical myocardial reperfusion. The hypothesis of this study is that colchicine, an anti-inflammatory agent, may lead to reduction in periprocedural infarct size, when administered during elective coronary artery bypass graft surgery.

Enrollment

60 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The study will enroll patients 18 years old or older who are eligible to undergo CABG surgery.

Exclusion criteria

Excluded are patients:

with age > 80 years old
scheduled for concomitant valve surgery
scheduled for coronary surgery without cardiopulmonary bypass
with peripheral vascular disease aﬀecting the upper limbs
with acute coronary syndrome within the previous 4 weeks
on inotropic or mechanical circulatory support before induction of anaesthesia
with any disorder that could potentially increase preoperative cTnI concentrations (eg, percutaneous coronary intervention within the previous 6 weeks)
with active inflammatory diseases, infectious diseases or known malignancy
under treatment with corticosteroids, anti-inflammatory agents or disease modifying agents
with known hypersensitivity-allergy to colchicine
under chronic treatment with colchicine
with severe renal failure (eGFR < 35 ml/min/1.73 m2)
with hepatic failure (Child - Pugh class B or C)